Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | PTAFR | P25105 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15393208 | 0.99 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL15393394 | 0.99 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL541141 | 0.99 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL1260913 | 0.99 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL1260696 | 0.99 | AKT1 (0.49) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL1261300 | 0.97 | AKT1 (0.50) | AKT1LMNAESR1ADORA3CDC25A | |
| Phosphoric Acid SCHEMBL2034350 | 0.96 | AKT1 (0.47) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL1260809 | 0.96 | AKT1 (0.49) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL1260704 | 0.96 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A | |
| SCHEMBL15393520 | 0.96 | LMNA (0.52) | AKT1LMNAESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2801401-B1 | OUTSTANDINGLY CONTAMINATION RESISTANT REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | LG CHEMICAL LTD (KR) | 2018-12-12 | — | — | EP | claimed |
| EP-2801401-A1 | OUTSTANDINGLY CONTAMINATION RESISTANT REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | LG Chem, Ltd. (KR) | 2014-11-12 | — | — | EP | claimed |
| US-8646617-B2 | Reverse osmosis membrane having good antifouling properties and method of manufacturing the same | LG CHEM, LTD. (KR) | 2014-02-11 | — | — | US | claimed |
| US-20130306550-A1 | REVERSE OSMOSIS MEMBRANE HAVING GOOD ANTIFOULING PROPERTIES AND METHOD OF MANUFACTURING THE SAME | LG CHEM, LTD. (KR) | 2013-11-21 | — | — | US | claimed |
| EP-2801401-B1 | OUTSTANDINGLY CONTAMINATION RESISTANT REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | LG CHEMICAL LTD (KR) | 2018-12-12 | — | — | EP | disclosed |
| US-9216241-B2 | Medical device and method for producing the same | KYOCERA MEDICAL CORPORATION (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2801401-A1 | OUTSTANDINGLY CONTAMINATION RESISTANT REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | LG Chem, Ltd. (KR) | 2014-11-12 | — | — | EP | disclosed |
| EP-2233159-B1 | MEDICAL DEVICE AND METHOD FOR MANUFACTURE THEREOF | KYOCERA MEDICAL CORP (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-8646617-B2 | Reverse osmosis membrane having good antifouling properties and method of manufacturing the same | LG CHEM, LTD. (KR) | 2014-02-11 | — | — | US | disclosed |
| US-20130306550-A1 | REVERSE OSMOSIS MEMBRANE HAVING GOOD ANTIFOULING PROPERTIES AND METHOD OF MANUFACTURING THE SAME | LG CHEM, LTD. (KR) | 2013-11-21 | — | — | US | disclosed |
| US-20110027757-A1 | MEDICAL DEVICE AND METHOD FOR PRODUCING THE SAME | Japan Medical Materials Corporation and The University of Tokyo | 2011-02-03 | — | — | US | disclosed |
| EP-2233159-A1 | MEDICAL DEVICE AND METHOD FOR MANUFACTURE THEREOF | Japan Medical Materials Corporation (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20070287094-A1 | Planographic Printing Plate, Planographic Printing Plate Material, Support for Planographic Printing Plate Material, and Planographic Printing Method | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070065379-A1 | Microcapsules having an aqueous core and their use in cosmetics | L'OREAL (FR) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065379-A1 | Microcapsules having an aqueous core and their use in cosmetics | PHOSPHO1, SGMS1, CUTA | AKT1 668/4885LMNA 737/4885ESR1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.